条条大路通罗马？

别愁

"curative"英文原解为“tending or able to cure"。所以，"curative response" 积极一点的理解是“能治愈的响应".
希望更多的人能象楼主一样关注国外新药的研发进展！

[ 本帖最后由 别愁 于 2010-2-4 11:42 编辑 ]

shiweibuyi

shiweibuyi

CATBALOU

共舞知识很深

shiweibuyi

shiweibuyi

lemonades

From medhelp hbv forum:
by stefano170669


tenofovir (viread) is much stronger than baraclude and has 0 resistance but have some mild sides in 1% cases of kidney toxicity and bone demineralization.seroconvertion on tenofovir is similar to interferon and in case of past use of lam with resistance or adefovir with no resistance is the best safe choice.

baraclude (entecavir) has 1.2% of resistance and on animal models causes cancer at doses 40 times higher than those in humans.seroconvertion is very low at 5% in 5 years and only on hbe pos.

at the moment i am on entecavir but i would prefer tenofovir which is much stronger and since replicor antiviral is on phase II (it has hbs seroconvertion in high percentage and in short time, animal model 55% in 28 days) it won't take long to have it on the market and leave both tenofovir and entecavir.replicor drug has no reistance and no sides.

also alinia is much stronger than tenofovir and entecavir with no reistance and no sides and should be a safe combo especially when we will have slow release high dose available

so my suggestion is keep baraclude if you are naive and hbvdna und or otherwise go for tenofovir to be safer on resistance

我真希望自己还能等着他们上市。还是有很多有希望的药物的。

[ 本帖最后由 lemonades 于 2010-2-11 10:00 编辑 ]

lemonades

楼主说的就是其中的一个。现在看上去也挺有希望，但还在II期，我引用的那个作者看上去很乐观，觉得II期的药物能很快上市。

别愁

继续关注，希望有进一步的好消息。

lemonades

http://www.replicor.com
http://www.replicor.com/debut_anglais2.htm
这个药的网页。
在人体的初步实验效果也很好，和鸭模型差不多，今年3月份会在北京报道这个药在人体的初步实验数据。目前为止没副作用和耐药性。

看来希望真的很大。大家好好保重，等着新药上市啊。

不过我持保留意见，因为此物分子量大，不好做成制剂，生物利用度也低。不过既然他们已经在人体做过实验了，想必小规模生产是没问题的。

[ 本帖最后由 lemonades 于 2010-4-12 06:14 编辑 ]